drugset / Trial / NCT01117220

Safety And Efficacy Of Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed) (Protocol A1281196)

NCT01117220

Phase 3 Withdrawn Viatris Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine if flexibly-dosed ziprasidone is safe and effective for the treatment of children and adolescents (ages 10-17) with Bipolar l Disorder (Manic or Mixed).

Timeline

Start
2010-06
Primary completion
2011-04
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ziprasidone Small molecule 40 mg Oral
Comparator Ziprasidone Small molecule 80 mg Oral

Indications